肝癌电子杂志 ›› 2020, Vol. 7 ›› Issue (2): 2-11.
中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组
收稿日期:2020-05-06
出版日期:2020-06-30
发布日期:2020-07-23
通讯作者:
* 蔡建强 E-mail: caijianqiang@cicams.ac.cn;周爱萍 E-mail: zhouap1825@126.com
基金资助:
Received:2020-05-06
Online:2020-06-30
Published:2020-07-23
中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组. 肝癌靶向治疗专家共识（草案）[J]. 肝癌电子杂志, 2020, 7(2): 2-11.
| [1] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28. [2] VOGEL A, CERVANTES A, CHAU I, et al. Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†[J]. Ann Oncol, 2018, 29(Supplement_4):iv238-iv255. [3] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南[M]. 北京:人民卫生出版社, 2020:1-131. [4] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390. [5] CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34. [6] KUDO M, FINN RS, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173. [7] BI F, QIN S, GU S, et al.Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phaseⅡ/Ⅲtrial[J]. J Clin Oncol, 2020,38(15_suppl):4506. [8] 秦叔逵, 白玉贤, 欧阳学农, 等. 阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J]. 临床肿瘤学杂志, 2017,22(12):1057-1065. [9] BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66. [10] LI Q, QIN S, GU S, et al.Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phaseⅢstudy[J]. J Clin Oncol , 2020, 38(15_suppl):4507. [11] ABOU-ALFA GK, MEYER T, CHENG AL, et al.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1):54-63. [12] ZHU AX, KANG YK, YEN CJ, et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2):282-296. [13] ZHOU A, SUN Y, ZHANG W, et al.751P - Anlotinib for advanced hepatocellular carcinoma: Interim results from the phaseⅡ ALTER0802 study[J]. Annals of Oncology, 2019, 30:v288-v289. [14] FINN R S, QIN S, IKEDA M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905. [15] ANDREW X.A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)[C/OL].Andrew X. ASCO, Chicago, 2020. [16] XU J, ZHANG Y, JIA R, et al.Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2):515-523. [17] EL-KHOUEIRY AB, KIM RD, et al.Phase Ⅰ b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)[C/OL].Anthony B.ASCO-GI, San Francisco, 2020. [18] KUDO M, IKEDA M, MOTOMURA K, et al.Unresectable hepatocellular carcinoma (uHCC): Study 117[C/OL]. Masatoshi Kudo. ASCO-GI, San Francisco, 2020. [19] ZHANG W, BI XY, SUN YK, et al.Preliminary results of sintilimab plus different dose of IBI305 (anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma: A phaseⅠ b study [C/OL]. ASCO, Chicago, 2020. [20] ZHU AX, ROSMORDUC O, EVANS TR, et al.SEARCH: a phase Ⅲ, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol, 2015,33(6):559-566. [21] ABOU-ALFA GK, JOHNSON P, KNOX JJ, et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial[J]. JAMA, 2010, 304(19):2154-2160. [22] SRIMUNINNIMIT V, SRIURANPONG V, SUWANVECHO S.Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phaseⅡstudy[J]. Asia Pac J Clin Oncol, 2014, 10(3):255-260. [23] PETRINI I, LENCIONI M, RICASOLI M, et al.PhaseⅡtrial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2012, 69(3):773-780. [24] LIU Y, YUE H, XU S, et al.First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study[J]. Int J Clin Oncol, 2015, 20(5):952-959. [25] BRUIX J, TAKAYAMA T, MAZZAFERRO V, et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(13):1344-1354. [26] WANG SN, CHUANG SC, LEE KT.Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study[J]. Hepatol Res, 2014,44(5):523-531. [27] ZHANG XP, CHAI ZT, GAO YZ, et al.Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB (Oxford), 2019, 21(12):1687-1696. [28] HUANG Y, CHENG X, SUN P, et al.Supplementary sorafenib therapies for hepatocellular carcinoma-a systematic review and meta-analysis: supplementary sorafenib for liver cancer[J]. J Clin Gastroenterol, 2019, 53(7):486-494. [29] LIAO Y, ZHENG Y, HE W, et al.Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence[J]. Oncol Lett, 2017,13(2):984-992. [30] ZHUANG L, WEN T, XU M, et al.Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma[J]. Arch Med Sci, 2017,13(6):1383-1393. [31] WAGHRAY A, BALCI B, EL-GAZZAZ G, et al.Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant, 2013, 27(4):555-561. [32] CHAGAS AL, FELGA G, DINIZ MA, et al.Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival[J]. Eur J Gastroenterol Hepatol, 2019, 31(9):1148-1156. [33] KANG SH, CHO H, CHO EJ, et al.Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence[J]. J Korean Med Sci, 2018, 33(45):e283. [34] DE'ANGELIS N, LANDI F, NENCIONI M, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Prog Transplant, 2016, 26(4):348-355. [36] DE'ANGELIS N, LANDI F, CARRA MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review[J]. World J Gastroenterol, 2015, 21(39):11185-11198. [36] IAVARONE M, INVERNIZZI F, CZAUDERNA C, et al.Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation[J]. Am J Transplant, 2019, 19(11):3176-3184. [37] VIVARELLI M, CUCCHETTI A, LA BARBA G, et al.Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5):857-862. [38] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2):275-280. [39] JUNG DH, TAK E, HWANG S, et al.Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018,24(7):932-945. [40] INVERNIZZI F, IAVARONE M, ZAVAGLIA C, et al.Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation[J]. Transplantation, 2020,104(3):568-574. [41] SHETTY K, DASH C, LAURIN J.Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma[J]. J Transplant, 2014, 2014:913634. [42] SIEGEL AB, EL-KHOUEIRY AB, FINN RS, et al.Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma[J]. Liver Cancer, 2015, 4(2):115-125. [43] HUANG L, LI GM, ZHU JY, et al.Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study[J]. Onco Targets Ther, 2012, 5:457-462. [44] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 肝癌电子杂志,2020, 7(1):5-23. [45] NI JY, SUN HL, LUO JH, et al.Transarterial chemoembolization and sorafenib combined with microwave ablation for advanced primary hepatocellular carcinoma: a preliminary investigation of safety and efficacy[J]. Cancer Manag Res, 2019, 11:9939-9950. [46] CHEN SW, LIN LC, KUO YC, et al.Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2014, 88(5):1041-1047. [47] ZHAO Y, ZHU X, WANG H, et al.Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion[J]. Front Oncol, 2019, 9:1065. [48] KIM BK, KIM D Y, BYUN HK, et al.Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: A prospective phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2020,107(1):106-115. [49] NOMURA T, TANI J, DEGUCHI A, et al.Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion[J]. Mol Clin Oncol, 2019, 11(5):447-454. [50] 尹小兰, 许青. 索拉非尼联合立体定向精确放疗治疗肝癌肺转移疗效观察[J]. 中国临床医学, 2016, 23(5):618-624. [51] LENCIONI R, LLOVET JM, HAN G, et al.Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial[J]. J Hepatol, 2016, 64(5):1090-1098. [52] MEYER T, FOX R, MA YT, et al.Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): A randomised placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(8):565-575. [53] KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2019, gutjnl-2019-318934. [54] ZHU K, CHEN J, LAI L, et al.Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study[J]. Radiology, 2014, 272(1):284-293. [55] ZHANG X, WANG K, WANG M, et al.Transarterial chemoem-bolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(17): 29416-29427. [56] QU XD, CHEN CS, WANG JH, et al.The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma[J]. BMC Cancer, 2012, 12:263. [57] YOO DJ, KIM KM, JIN YJ, et al.Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?[J]. J Gastroenterol Hepatol, 2011, 26(1):145-154. [58] QIU Z, SHEN L, CHEN S, et al.Efficacy of apatinib in transcatheter arterial chemoembolization (TACE) refractory intermediate and advanced-stage hepatocellular carcinoma:A propensity score matching analysis[J]. Cancer Manag Res, 2019, 11:9321-9330. [59] CHOI GH, SHIM JH, KIM MJ, et al.Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses[J]. Radiology, 2013, 269(2):603-611. [60] CHENG S, CHEN M, CAI J, et al.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition)[J]. Liver Cancer, 2020, 9(1):28-40. [61] IKEDA M, SHIMIZU S, SATO T, et al.Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phaseⅡtrial[J]. Ann Oncol, 2016, 27(11):2090-2096. [62] KUDO M, UESHIMA K, YOKOSUKA O, et al.Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):424-432. [63] HE M, LI Q, ZOU R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019,5(7):953-960. [64] KUDO M, LENCIONI R, MARRERO JA, et al.Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study[J]. Liver Int, 2016, 36(8):1196-1205. [65] YE SL, CHEN X, YANG J, et al.Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study[J]. Oncotarget, 2016, 7(6):6639-6648. [66] BEKAII-SAAB TS, OU FS, AHN DH, et al.Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2019,20(8):1070-1082. [67] KUDO T, KATO T, KAGAWA Y, et al.PhaseⅡdose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy[J]. Annals of Oncology, 2017,28:v208. [68] ARGILES G, MARGALEF NM, VALLADARES-AYERBES M, et al.Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)[J]. Annals of Oncology, 2019, 30:v135. [69] YOO C, PARK JW, KIM YJ, et al.Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma[J]. Invest New Drugs, 2019, 37(3):567-572. [70] KIM K, JHA R, PRINS PA, et al.Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment[J]. Cancer Chemother Pharmacol, 2017, 80(5):945-954. [71] WANG W, TSUCHIYA K, KUROSAKI M, et al.Sorafenib-regorafenib sequential therapy in Japanese patients with unresectable hepatocellular carcinoma-relative dose intensity and post-regorafenib therapies in real world practice[J]. Cancers (Basel), 2019,11(10). [72] LIM H Y, MERLE P, FINN RS, et al.Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial[J]. Journal of Clinical Oncology, 2020, 38(4_suppl):542. [73] TIAN A, ZHOU A, BI X, et al.Efficacy of topical compound Danxiong granules for treatment of dermatologic toxicities induced by targeted anticancer therapy: A randomized, double-blind, placebo-controlled trial[J]. Evid Based Complement Alternat Med, 2017, 2017:3970601. [74] LAM W, JIANG Z, GUAN F, et al.PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment[J]. Sci Rep, 2015, 5:9384. [75] BARTON DL, LIU H, DAKHIL SR, et al.Wisconsin ginseng (panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2[J]. J Natl Cancer Inst, 2013, 105(16):1230-1238. [76] ALSINA A, KUDO M, VOGEL A, et al.Effects of subsequent systemic anticancer medication following first-line lenvatinib: A post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma[J]. Liver Cancer, 2020, 9(1):93-104. [77] KUDO M, FINN RS, QIN S, et al.Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase Ⅲstudy of lenvatinib (REFLECT)[J]. Journal of Clinical Oncology, 2019, 37(4_suppl):186. [78] VINCENZI B, DI MAIO M, SILLETTA M, et al.Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis[J]. PLoS One, 2015, 10(7):e133488. [79] JUNG ES, KIM JH, YOON EL, et al.Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. J Hepatol, 2013, 58(6):1181-1187. [80] WANG P, TAN G, ZHU M, et al.Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(1):1-8. [81] BRUIX J, CHENG AL, MEINHARDT G, et al.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phaseⅢstudies[J]. J Hepatol, 2017, 67(5):999-1008. [82] MARISI G, CUCCHETTI A, ULIVI P, et al.Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?[J]. World J Gastroenterol, 2018, 24(36):4152-4163. [83] SOLIMAN H, RINGASH J, JIANG H, et al.Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases[J]. J Clin Oncol, 2013, 31(31):3980-3986. [84] JIHYE C, JINSIL S.Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma[J]. Liver Cancer, 2012, 1(3-4):216-225. [85] BENSON AR, ABRAMS TA, BEN-JOSEF E, et al.NCCN clinical practice guidelines in oncology: hepatobiliary cancers[J]. J Natl Compr Canc Netw, 2009, 7(4):350-391. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
